Quest Partners LLC Purchases 3,223 Shares of Moderna, Inc. (NASDAQ:MRNA)

Quest Partners LLC boosted its position in Moderna, Inc. (NASDAQ:MRNAFree Report) by 239.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,567 shares of the company’s stock after acquiring an additional 3,223 shares during the period. Quest Partners LLC’s holdings in Moderna were worth $305,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the second quarter valued at about $26,000. Family Firm Inc. bought a new position in Moderna during the second quarter worth about $33,000. Bank & Trust Co bought a new position in Moderna during the second quarter worth about $36,000. Hanseatic Management Services Inc. bought a new position in Moderna during the second quarter worth about $48,000. Finally, Plato Investment Management Ltd boosted its holdings in Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 6.2 %

Shares of Moderna stock opened at $43.66 on Tuesday. The business’s 50 day simple moving average is $54.96 and its 200 day simple moving average is $93.71. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The firm has a market cap of $16.80 billion, a PE ratio of -7.50 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNAGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.39) EPS. On average, analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Monday, November 18th. Berenberg Bank started coverage on Moderna in a report on Tuesday, November 19th. They set a “hold” rating and a $42.00 target price on the stock. Barclays cut their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $84.00.

View Our Latest Research Report on Moderna

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,930 shares of company stock valued at $217,170 in the last 90 days. 15.20% of the stock is currently owned by insiders.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.